A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
A phase 3 trial of Trastuzumab deruxtecan in metastatic cancer, run by Daiichi Sankyo, now recruiting.
Overview
A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s) is a phase 3 interventional study registered as NCT06174987 by Daiichi Sankyo, with 50 participants planned, started 2024-01-05 and due to reach its primary completion in 2026-08-03. Interventions recorded: T-DXd. Conditions listed: Advanced Cancer, Metastatic Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialFirst-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
Shares Daiichi Sankyo, Metastatic cancer (cancer that has spread).
- TrialStudy of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Shares Daiichi Sankyo, Trastuzumab deruxtecan.
- TrialStudy of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-
Shares Daiichi Sankyo, Trastuzumab deruxtecan.
- TrialEIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors
Shares Trastuzumab deruxtecan, Metastatic cancer (cancer that has spread).
- TrialTrastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Shares Daiichi Sankyo, Trastuzumab deruxtecan.
- TrialSubstudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
Shares Daiichi Sankyo, Metastatic cancer (cancer that has spread).
- TrialA Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Shares Daiichi Sankyo, Trastuzumab deruxtecan, Metastatic cancer (cancer that has spread).
- TrialA Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors
Shares Daiichi Sankyo, Trastuzumab deruxtecan.